Abstract
Graft versus host disease (GVHD) is a T cell mediated phenomenon that arises following allogeneic haematopoietic stem cell transplantation, and may be particularly severe in the context of human leukocyte antigen (HLA) mismatched procedures. Although GVHD can be largely abrogated through T cell depletion, such measures result in loss of graft potency and reduced anti-viral and anti-leukaemic effects. The genetic modification of T cells to carry a suicide gene mechanism has been advocated as means of allowing T cells to be harnessed for their beneficial effects, and safely eliminated in the event of significant GVHD. The feasibility of the strategy has been demonstrated in clinical studies using T cells modified by retroviral transduction to encode the herpes simplex thymidine kinase (HSVTK) gene to treat patients with haematological malignancies. However, a number of limitations associated with current protocols have become apparent. Most notably, the process of retroviral transduction, which requires pre-activation of T cells, appears to impair subsequent functional potential. Efforts are now directed towards circumventing the pre-activation requirements of retroviral vectors by using alternative lentiviral systems, in association with improved suicide gene / prodrug combinations.
Keywords: suicide gene, graft versus host disease, retroviral vectors, stem cell transplantation
Current Gene Therapy
Title: T Cell Suicide Gene Therapy to Aid Haematopoietic Stem Cell Transplantation
Volume: 5 Issue: 1
Author(s): W. Qasim, H. B. Gaspar and A. J. Thrasher
Affiliation:
Keywords: suicide gene, graft versus host disease, retroviral vectors, stem cell transplantation
Abstract: Graft versus host disease (GVHD) is a T cell mediated phenomenon that arises following allogeneic haematopoietic stem cell transplantation, and may be particularly severe in the context of human leukocyte antigen (HLA) mismatched procedures. Although GVHD can be largely abrogated through T cell depletion, such measures result in loss of graft potency and reduced anti-viral and anti-leukaemic effects. The genetic modification of T cells to carry a suicide gene mechanism has been advocated as means of allowing T cells to be harnessed for their beneficial effects, and safely eliminated in the event of significant GVHD. The feasibility of the strategy has been demonstrated in clinical studies using T cells modified by retroviral transduction to encode the herpes simplex thymidine kinase (HSVTK) gene to treat patients with haematological malignancies. However, a number of limitations associated with current protocols have become apparent. Most notably, the process of retroviral transduction, which requires pre-activation of T cells, appears to impair subsequent functional potential. Efforts are now directed towards circumventing the pre-activation requirements of retroviral vectors by using alternative lentiviral systems, in association with improved suicide gene / prodrug combinations.
Export Options
About this article
Cite this article as:
Qasim W., Gaspar B. H. and Thrasher J. A., T Cell Suicide Gene Therapy to Aid Haematopoietic Stem Cell Transplantation, Current Gene Therapy 2005; 5 (1) . https://dx.doi.org/10.2174/1566523052997497
DOI https://dx.doi.org/10.2174/1566523052997497 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and SARs of Coumarin Fused 1,5-Benzothiazepines as Novel Anticancer and Antioxidant Agents
Mini-Reviews in Organic Chemistry Recent Evidence of the Regulatory Role of PPARs in Neural Stem Cells and Their Underlying Mechanisms for Neuroprotective Effects
Current Stem Cell Research & Therapy Nanodiamonds as a New Horizon for Pharmaceutical and Biomedical Applications
Current Drug Delivery Interlocked Systems in Nanomedicine
Current Topics in Medicinal Chemistry In vivo Radiosensitization of Human Glioma U87 Cells Induced by Upregulated Expression of DUSP-2 after Treatment with Curcumin
Current Signal Transduction Therapy Subject Index To Volume 7
Current Pharmaceutical Biotechnology Cancer Therapy: Targeting Mitochondria and other Sub-cellular Organelles
Current Pharmaceutical Design Overview of Mechanisms of Cancer Stem Cell Drug Resistance
Current Signal Transduction Therapy Editorial (Thematic Issue: Mechanisms of Cancer Stem Cell Resistance to Chemotherapy)
Current Signal Transduction Therapy miR-15b and miR-21 as Circulating Biomarkers for Diagnosis of Glioma
Current Genomics Cellular Uptake and Organ Accumulation of Amphipolar Metallocorroles with Cytoprotective and Cytotoxic Properties
Anti-Cancer Agents in Medicinal Chemistry Epidermal Growth Factor Receptor as a Target for Anti-Cancer Agent Design
Anti-Cancer Agents in Medicinal Chemistry New Functions of the Inositol Polyphosphate 5-Phosphatases in Cancer
Current Pharmaceutical Design Tamoxifen as a Powerful Neuroprotectant in Experimental Stroke and Implications for Human Stroke Therapy
Recent Patents on CNS Drug Discovery (Discontinued) The Targets of Curcumin
Current Drug Targets Advances in Cancer Stem Cell Therapy: Targets and Treatments
Recent Patents on Regenerative Medicine Molecular Targeted Approaches to Cancer Therapy and Prevention Using Chalcones
Current Cancer Drug Targets The Use of Fas Ligand, TRAIL and Bax in Gene Therapy of Prostate Cancer
Current Gene Therapy Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design